{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:36:46Z","timestamp":1787020606426,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate the risk factors associated with the development of occult peritoneal metastasis in advanced gastric cancer, and establish and externally validate a nomogram for predicting the occurrence of occult peritoneal metastasis in patients with advanced gastric cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 111 patients with advanced gastric cancer who underwent laparoscopic exploration or peritoneal lavage cytology examination at the Affiliated Drum Tower Hospital of Nanjing University Medical School from August 2014 to December 2021 were retrospectively analyzed. The patients diagnosed between 2019 and 2021 were assigned to the training set (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200964), while those diagnosed between 2014 and 2016 constituted the external validation set (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200947). In the training set, patients were classified into two groups based on preoperative imaging and postoperative pathological data: the occult peritoneal metastasis group (OPMG) and the peritoneal metastasis negative group (PMNG). In the validation set, patients were classified into the occult peritoneal metastasis group (CY1P0, OPMG) and the peritoneal metastasis negative group (CY0P0, PMNG) based on peritoneal lavage cytology results. A nomogram was constructed using univariate and multivariate analyses. The performance of the nomogram was evaluated using Harrell\u2019s C-index, the area under the receiver operating characteristic curve (AUC), decision curve analysis (DCA), and calibration plots.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study analyzed 22 potential variables of OPM in 111 gastric cancer patients who underwent laparoscopic exploration or peritoneal lavage cytology examination. Logistic regression analysis results showed that Lauren classification, CLDN18.2 score and CA125 were independent risk factors for OPM in patients with gastric cancer. We developed a simple and easy-to-use prediction nomogram of occult peritoneal metastasis in advanced gastric cancer. This nomogram had an excellent diagnostic performance. The AUC of the bootstrap model in the training set was 0.771 and in the validation set was 0.711. This model showed a good fitting and calibration and positive net benefits in decision curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We have developed a prediction nomogram of OPM for gastric cancer. This novel nomogram has the potential to enhance diagnostic accuracy for occult peritoneal metastasis in gastric cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-023-03188-2","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:02:02Z","timestamp":1697155322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Establishment and verification of prediction model of occult peritoneal metastasis in advanced gastric cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Hengfei","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangkang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linsen","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"issue":"3","key":"3188_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"3188_CR2","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.ejca.2015.07.026","volume":"51","author":"LA Anderson","year":"2015","unstructured":"Anderson LA, Tavilla A, Brenner H, Luttmann S, Navarro C, Gavin AT, et al. Survival for oesophageal, stomach and small intestine cancers in Europe 1999\u20132007: results from EUROCARE-5. Eur J Cancer. 2015;51(15):2144\u201357.","journal-title":"Eur J Cancer"},{"key":"3188_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2482-14-29","volume":"14","author":"WJ Zeng","year":"2014","unstructured":"Zeng WJ, Hu WQ, Wang LW, Yan SG, Li JD, Zhao HL, et al. Long term follow up and retrospective study on 533 gastric cancer cases. BMC Surg. 2014;14:29.","journal-title":"BMC Surg"},{"key":"3188_CR4","doi-asserted-by":"crossref","unstructured":"Sarela AI, Yelluri S. Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary? Arch Surg. 2007;142(2):143\u20139; discussion 9.","DOI":"10.1001\/archsurg.142.2.143"},{"key":"3188_CR5","doi-asserted-by":"crossref","unstructured":"Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014;40(1):12\u201326.","DOI":"10.1016\/j.ejso.2013.10.019"},{"issue":"19","key":"3188_CR6","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36(19):1922\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3188_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/annonc\/mdz001","volume":"30","author":"D Dong","year":"2019","unstructured":"Dong D, Tang L, Li ZY, Fang MJ, Gao JB, Shan XH, et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann Oncol. 2019;30(3):431\u20138.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"3188_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s10120-016-0684-3","volume":"20","author":"H Ishigami","year":"2017","unstructured":"Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer. 2017;20(Suppl 1):128\u201334.","journal-title":"Gastric Cancer"},{"issue":"3","key":"3188_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s10120-020-01137-6","volume":"24","author":"T Yamaguchi","year":"2021","unstructured":"Yamaguchi T, Takashima A, Nagashima K, Terashima M, Aizawa M, Ohashi M, et al. Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): a multi-institutional retrospective study. Gastric Cancer. 2021;24(3):701\u20139.","journal-title":"Gastric Cancer"},{"issue":"3","key":"3188_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.crad.2012.07.015","volume":"68","author":"S Burbidge","year":"2013","unstructured":"Burbidge S, Mahady K, Naik K. The role of CT and staging laparoscopy in the staging of gastric cancer. Clin Radiol. 2013;68(3):251\u20135.","journal-title":"Clin Radiol"},{"issue":"6","key":"3188_CR11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.addr.2005.01.006","volume":"57","author":"K Swisshelm","year":"2005","unstructured":"Swisshelm K, Macek R, Kubbies M. Role of claudins in tumorigenesis. Adv Drug Deliv Rev. 2005;57(6):919\u201328.","journal-title":"Adv Drug Deliv Rev"},{"issue":"23","key":"3188_CR12","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624\u201334.","journal-title":"Clin Cancer Res"},{"key":"3188_CR13","doi-asserted-by":"crossref","unstructured":"Kim SR, Shin K, Park JM, Lee HH, Song KY, Lee SH, et al. Clinical significance of CLDN18.2 expression in metastatic diffuse-type gastric cancer. J Gastric Cancer. 2020;20(4):408\u201320.","DOI":"10.5230\/jgc.2020.20.e33"},{"issue":"4","key":"3188_CR14","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1245\/s10434-019-07812-y","volume":"27","author":"ZY Li","year":"2020","unstructured":"Li ZY, Tang L, Li ZM, Li YL, Fu J, Zhang Y, et al. Four-point computed tomography scores for evaluation of occult peritoneal metastasis in patients with gastric cancer: a region-to-region comparison with staging laparoscopy. Ann Surg Oncol. 2020;27(4):1103\u20139.","journal-title":"Ann Surg Oncol"},{"key":"3188_CR15","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101\u201312.","DOI":"10.1007\/s10120-011-0041-5"},{"issue":"12","key":"3188_CR16","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2488::AID-CNCR12>3.0.CO;2-1","volume":"83","author":"B Nakata","year":"1998","unstructured":"Nakata B, Hirakawa YSCK, Kato Y, Yamashita Y, Maeda K, Onoda N, et al. Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer. 1998;83(12):2488\u201392.","journal-title":"Cancer"},{"issue":"7","key":"3188_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1055\/s-2002-33228","volume":"34","author":"T Fujimura","year":"2002","unstructured":"Fujimura T, Kinami S, Ninomiya I, Kitagawa H, Fushida S, Nishimura G, et al. Diagnostic laparoscopy, serum CA125, and peritoneal metastasis in gastric cancer. Endoscopy. 2002;34(7):569\u201374.","journal-title":"Endoscopy"},{"issue":"10","key":"3188_CR18","doi-asserted-by":"publisher","first-page":"9190","DOI":"10.1074\/jbc.M312372200","volume":"279","author":"A Rump","year":"2004","unstructured":"Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279(10):9190\u20138.","journal-title":"J Biol Chem"},{"issue":"1","key":"3188_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1476-4598-5-50","volume":"5","author":"JA Gubbels","year":"2006","unstructured":"Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5(1):50.","journal-title":"Mol Cancer"},{"issue":"1","key":"3188_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/SLA.0000000000002040","volume":"267","author":"JH Lee","year":"2018","unstructured":"Lee JH, Chang KK, Yoon C, Tang LH, Strong VE, Yoon SS. Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma. Ann Surg. 2018;267(1):105\u201313.","journal-title":"Ann Surg"},{"issue":"1","key":"3188_CR21","first-page":"674","volume":"18","author":"M Perrot-Applanat","year":"2019","unstructured":"Perrot-Applanat M, Vacher S, Pimpie C, Chemlali W, Derieux S, Pocard M, et al. Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer. Oncol Lett. 2019;18(1):674\u201386.","journal-title":"Oncol Lett"},{"issue":"9","key":"3188_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074757","volume":"8","author":"T Oshima","year":"2013","unstructured":"Oshima T, Shan J, Okugawa T, Chen X, Hori K, Tomita T, et al. Down-regulation of claudin-18 is associated with the proliferative and invasive potential of gastric cancer at the invasive front. PLoS ONE. 2013;8(9): e74757.","journal-title":"PLoS ONE"},{"issue":"6","key":"3188_CR23","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1053\/j.gastro.2018.08.041","volume":"155","author":"SJ Hagen","year":"2018","unstructured":"Hagen SJ, Ang LH, Zheng Y, Karahan SN, Wu J, Wang YE, et al. Loss of tight junction protein claudin 18 promotes progressive neoplasia development in mouse stomach. Gastroenterology. 2018;155(6):1852\u201367.","journal-title":"Gastroenterology"},{"issue":"4","key":"3188_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/biot.201300456","volume":"9","author":"K Schnatbaum","year":"2014","unstructured":"Schnatbaum K, Schmoldt HU, Daneschdar M, Plum LM, Jansong J, Zerweck J, et al. Peptide microarrays enable rapid mimotope optimization for pharmacokinetic analysis of the novel therapeutic antibody IMAB362. Biotechnol J. 2014;9(4):545\u201354.","journal-title":"Biotechnol J"},{"key":"3188_CR25","doi-asserted-by":"crossref","unstructured":"W\u00f6ll S, Schlitter AM, Dhaene K, Roller M, Esposito I, Sahin U, et al. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014;134(3):731\u20139.","DOI":"10.1002\/ijc.28400"},{"key":"3188_CR26","doi-asserted-by":"crossref","unstructured":"Sahin U, T\u00fcreci \u00d6, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5):609\u201319.","DOI":"10.1016\/j.annonc.2021.02.005"},{"key":"3188_CR27","doi-asserted-by":"crossref","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368.","DOI":"10.1016\/S0140-6736(23)00620-7"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-023-03188-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-023-03188-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-023-03188-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T08:28:03Z","timestamp":1700382483000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-023-03188-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3188"],"URL":"https:\/\/doi.org\/10.1186\/s12957-023-03188-2","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"22 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The entire process of this study followed the ethical standards of Declaration of Helsinki and its later amendments. This study has been approved by the Ethics Committees of Nanjing Drum Tower Hospital and informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"320"}}